Contained by C

Proof from most randomized health check trials put forward that vitamin C supplementation, typically in grouping with other micro nutrients, does not concern tumor risk. In the Supplementation en Vitamins ET Minotaur Antioxidants’ (SU.VI.MAX) revise, a randomized, double-blind, placebo-controlled trial strong French adults received antioxidant supplementation with 120 mg scorbutic acid, 30 mg vitamin E, 6 mg beta-carotene, 100 mcg selenium, and 20 mg zinc, or placebo. After a median follow-up time of 7.5 years, antioxidant supplementation lowered total cancer frequency in men, but not in women. In adding, baseline antioxidant standing was related to cancer danger in men, but not in women .Supplements of 500 mg/day vitamin C plus 400 IU vitamin E every other day for a mean follow-up period of 8 years failed to reduce the risk of prostate or total cancer compared with placebo in adult and older men participating in the Physicians' Health Study II .comparable findings were reported in women participating in the Women's Antioxidant Cardiovascular Study .Compared with placebo, supplementation with vitamin C (500 mg/day) for an average of 9.4 years had no significant result on total cancer incidence or cancer death. In a large imposition trial conducted in Lillian, China, daily addition of vitamin C (120 mg) plus molybdenum (30 mcg) for 5–6 years did not significantly affect the risk of developing esophageal or gastric cancer .Moreover, during 10 years of follow-up, this supplementation regime failed to appreciably affect total morbidity or mortality from esophageal, gastric, or other cancers .A 2008 review of vitamin C and other antioxidant supplements for the prevention of gastrointestinal cancers found no convincing evidence that vitamin C (or beta-carotene, vitamin A, or vitamin E) prevents gastrointestinal cancers .A similar appraisal by Coulter and age group found that vitamin C supplementation, in combination with vitamin E, had no significant effect on death risk due to cancer in healthy individuals .At this time, the evidence is clashing on whether dietary vitamin C intake affects cancer risk. Consequences from most medical trials suggest that modest vitamin C supplementation alone or with other nutrients offers no benefit in the prevention of cancer. A substantial limitation in interpreting many of these studies is that investigators did not measure vitamin C concentrations before or after supplementation. Plasma and tissue concentrations of vitamin C are tightly prohibited in humans. At daily intakes of 100 mg or higher, cells appear to be saturated and at intakes of at least 200 mg, plasma concentrations enlarge only marginally .If subjects' vitamin C levels were already close to diffusion at study entry, supplementation would be probable to have made little or no distinction on exact outcomes .

Protector of cancer

All through the 1970s, studies by Cameron, Campbell, and Pauling discretionary that high-dose vitamin C has useful property on quality of life and endurance time in patients with incurable cancer .However, some consequent studies—including a randomized, double-blind, placebo-controlled experimental trial by Mortal and colleagues at the Mayo Clinic did not bear these findings. In the Mortal study, patients with advanced correctional cancer who received 10 g/day vitamin C fared no better than those getting a placebo. The authors of a 2003 review assessing the effects of vitamin C in patients with superior cancer completed that vitamin C confers no significant mortality benefit Emerging study suggests that the route of vitamin C administration (intravenous vs. oral) could make clear the conflicting findings Most intervention trials, together with the one conducted by Mortal and colleagues, used only oral direction, whereas Cameron and colleagues used a grouping of oral and intravenous (IV) administration. Oral administration of vitamin C, even of very large doses, can raise plasma vitamin C concentrations to a most of only 220 micro mole/L, whereas IV administration can make plasma concentration as high as 26,000 micro mole/L Concentrations of this magnitude are selectively toxicity to tumor cells in nitro .Research in mice suggests that pharmacological doses of IV vitamin C might show undertake in treating otherwise difficult-to-treat tumors .A high attention of vitamin C may act as a pro-oxidant and generate hydrogen remove the color that has selective toxicity toward cancer cells .Based on these findings and a few case reports of patients with advanced cancers who had remarkably long endurance times following administration of high-dose IV vitamin C, some researchers support reassessment of the use of high-dose IV vitamin C as a drug to treat cancer .As discussed below, it is uncertain whether supplemental vitamin C and other antioxidants might interact with chemotherapy and/or energy .Therefore, individuals undergoing these actions should consult with their oncologist earlier to taking vitamin C or other antioxidant supplements, particularly in high doses .

Additional dieses

proof from lots of epidemiological studies suggests that tall intakes of fruits and vegetables are allied with a condensed risk of cardiovascular disease .This association might be partly attributable to the antioxidant content of these foods because oxidation hurt, together with oxidation modification of low-density proteins, is a major cause of cardiovascular disease .In addition to its antioxidant properties, vitamin C has been shown to reduce mono cot observance to the endothelial, advance endothelial-dependent citric oxide production and dilatation, and reduce vascular smooth-muscle-cell apoptosis, which prevents plaque volatility in atherosclerosis .Results from forthcoming studies probing associations between vitamin C intake and cardiovascular infection risk are inconsistent .In the Nurses' Health Study, a 16-year probable study involving 85,118 female nurses, total intake of vitamin C from both dietary and supplemental source was inversely associated with coronary heart disease risk .However, intake of vitamin C from diet alone showed no significant relatives, suggesting that vitamin C harmonize users might be at lesser peril of coronary heart disease. A much smaller study indicated that postmenopausal women with diabetes who took at least 300 mg/day vitamin C supplements had increased cardiovascular disease mortality. A potential study in 20,649 British adults originate that those in the top quarterly of baseline plasma vitamin C concentrations had a 42% lower risk of stroke than those in the base quarterly .In male physicians participating in the Physicians' Health Study, use of vitamin C supplements for a mean of 5.5 years was not associated with a significant decrease in total cardiovascular disease mortality or coronary heart disease death .A pooled analysis of nine prospective studies that integrated 293,172 subjects free of coronary heart disease at baseline found that people who took ≥700 mg/day of supplemental vitamin C had a 25% lower risk of coronary heart disease frequency than those who took no supplemental vitamin C .The authors of a 2008 meta-analysis of prospective cohort studies, plus 14 studies reporting on vitamin C for a median follow-up of 10 years, concluded that dietary, but not supplemental, intake of vitamin C is inversely associated with coronary spirit virus danger .

Vitamin c advantage daises

Consequences from most medical interfering trials have disastrous to explain a beneficial consequence of vitamin C supplementation on the chief or secondary anticipation of cardiovascular disease. In the Women's Antioxidant Cardiovascular Study, a less vital expectancy trial involving 8,171 women elderly 40 years or older with a the past of cardiovascular disease, supplementation with 500 mg/day vitamin C for a mean of 9.4 years showed no overall effect on cardiovascular actions .likewise, vitamin C supplementation (500 mg/day) for a denote follow-up of 8 years had no effect on main cardiovascular events in male physicians enrolled in the Physicians' Health Study II .Other clinical trials have normally examined the effects on cardiovascular disease of supplements combining vitamin C with other antioxidants, such as vitamin E and beta-carotene, making it more difficult to isolate the possible contribution of vitamin C. The SU.VI.MAX study examined the belongings of a combination of vitamin C (120 mg/day), vitamin E (30 mg/day), beta-carotene (6 mg/day), selenium (100 mcg/day), and zinc (20 mg/day) in 13,017 French adults from the general inhabitants .After a center take notes time of 7.5 years, the combined supplements had no result on ischemic cardiovascular disease in either men or women. In the Women's Angiographic Vitamin and Estrogen (WAVE) study, involving 423 postmenopausal women with at least one coronary stenos is of 15%–75%, supplements of 500 mg vitamin C plus 400 IU vitamin E twice per day not only provided no cardiovascular benefit, but significantly increased all-cause humanity compare with placebo .